Edoxaban is a small-molecule oral anticoagulant developed by Daiichi Sankyo in Japan. It is a coagulation factor X (FXa) blocker that was launched in Japan in April 2011 and the United States in January 2015. Edoxaban can effectively inhibit coagulation factor Xa, thereby preventing thrombosis and preventing the occurrence of arterial and venous thromboembolism events.

Overview Of Market Development

With the intensification of global population aging, cardiovascular disease has become a major health problem on a global scale. As a new type of oral anticoagulant, Edoxaban has been widely used in the prevention and treatment of thrombosis and has therefore received widespread attention worldwide. According to our research data, the global market size of Edoxaban is estimated to be $2250 million in 2023.

In the future, with the development of the economy and the improvement of living standards, consumers in emerging markets will have an increasing demand for drugs, especially their dependence on high-quality and highly effective raw materials. This will provide more commercial opportunities for manufacturers of Edoxaban active pharmaceutical ingredient. In addition, technological progress has also provided new impetus for the development of the Edoxaban API market. For example, the advancement of biotechnology has made the research and production of Edoxaban active pharmaceutical ingredient more efficient; The application of new technologies such as artificial intelligence has made the production process more intelligent, improving production efficiency and product quality; The research and development of new drugs will also bring new opportunities for the development of the Edoxaban raw material market. Driven by numerous positive factors, it is expected that the global market size of Edoxaban will increase to $2691 million by 2025.

Source: www.globalmarketmonitor.com

Analysis of Market Development in Major Regions/Countries

Research shows that Europe is the largest consumer region in the industry. According to our data, the consumption of Edoxaban in Europe is expected to reach 21.65 tons in 2023, accounting for 41.24% of the global total consumption. From a national perspective, Japan is the largest consumer of Edoxaban globally. In 2023, the estimated consumption of Edoxaban in Japan is 19.79 tons, accounting for 37.70% of the total global consumption.

Edoxaban Consumption and Proportion Forecast by Region and Country in 2023

Regions/Countries	Consumption (Tons)	Proportion
North America	3.96	7.54%
Europe	21.65	41.24%
China	3.15	6.00%
Japan	19.79	37.70%
India	0.94	1.79%
South America	0.43	0.82.%
Middle East & AFRICA	0.52	0.98%

Source: www.globalmarketmonitor.com